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Protein foldingHereditary systemic amyloidosis caused by apolipoprotein A-I variants is a dominantly inherited disease
characterised by ﬁbrillar deposits mainly localized in the kidneys, liver, testis and heart. We have previously
shown that the apolipoprotein A-I variant circulates in plasma at lower levels than the wild-type form
(Mangione et al., 2001; Obici et al., 2004) thus raising the possibility that the amyloid deposits could
sequester the circulating amyloidogenic chain or that the intracellular quality control can catch and capture
the misfolded amyloidogenic chain before the secretion. In this study we have measured plasma levels of the
wild-type and the variant Leu75Pro apolipoprotein A-I in two young heterozygous carriers in which tissue
amyloid deposition was still absent. In both cases, the mutant was present at signiﬁcantly lower levels than
the wild-type form, thus indicating that the low plasma concentration of the apolipoprotein A-I variant is not
a consequence of the protein entrapment in the amyloid deposits. In order to explore the cell secretion of
amyloidogenic apolipoprotein A-I variants, we have studied COS-7 cells expressing either wild-type
apolipoprotein A-I or two amyloidogenic mutants: Leu75Pro and Leu174Ser. Quantiﬁcation of intracellular
and extracellular apolipoprotein A-I alongside the intra-cytoplasmatic localization indicates that, unlike the
wild-type protein, both variants are retained within the cells and mainly accumulate in the endoplasmic
reticulum. The low plasma concentration of amyloidogenic apolipoprotein A-I may therefore be ascribed to
the activity of the intracellular quality control that represents a ﬁrst line of defence against the secretion of
pathogenic variants.h-density lipoproteins; IFLM,
reticulum
try, University of Pavia, via
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Systemic amyloidoses caused by peculiar variants of globular
proteins such as lysozyme, transthyretin and apolipoprotein A-I
(apoA-I) are late onset, autosomal dominant genetic diseases [1]. Each
amyloidogenic globular protein causes a different clinical syndrome
since different tissues are involved. Moreover, different variants of the
same protein can target different tissues and, in a few cases,
heterogeneous phenotypes are reported even in the presence of
identical mutations [2]. Additional heterogeneity is related to theonset of the disease that can be highly variable even for the same
mutation [3]. A key element in the formation of ﬁbrils is represented
by the concentration of the amyloidogenic precursor both in the blood
and the extracellular matrix at the site of amyloid deposition [4]. A
seminal observation regarding the mechanisms responsible for the
selectivity of transthyretin deposition was reported by the Kelly's
group. They hypothesized that tissue damage can be related to the
local concentration of the protein, modulated by the variable
efﬁciency of the quality control of protein folding and secretion at
different sites of synthesis [5]. No data have been so far reported about
the possible role of the quality control in modulating the plasma
concentration of amyloidogenic apoA-I. Patients heterozygous for
apoA-I amyloidogenic mutations are frequently characterized by
hypoalphalipoproteinemia, with high density lipoproteins (HDL)
being never below 50% of the normal value [6]. Our research group
was the ﬁrst to observe that the wild-type chain is far more abundant
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Leu174Ser [7] and Leu75Pro variants [8]. Similar ﬁndings were
reported for the Leu64Pro mutation by the Solomon's group [9].
Different mechanisms, acting independently or in association one
with the other, might be involved in the altered metabolism of the
mutated protein compared to its normal counterpart, either at the
level of protein secretion during the folding process, or after its
secretion at the stage of apoA-I function and metabolism in HDL.
Clinical data and in vitro results of the presentmanuscript suggest that
the low plasma concentrations of the apoA-I amyloidogenic variants
largely depends on their impaired cellular secretion.
2. Materials and methods
2.1. Comparative quantiﬁcation of variant/wild-type chain in HDL
HDL were separated from plasma of two selected carriers of the
Leu75Pro mutation by sequential ultracentrifugation and apoA-I was
puriﬁed as described by Calabresi et al. [10]. Quantiﬁcation of wild-
type and Leu75Pro apoA-I was indirectly derived, as previously
described [7], from the measurement of speciﬁc peptides obtained
from the digestion of apoA-I with V8 protease (Pierce). The digestion
was carried out in bicarbonate buffer (50 mM at pH 8.0, 2 mM EDTA)
for 12 h at 37 °C at an enzyme/protein ratio of 1:50 (w/w). Peptides
obtained were then separated by reversed phase HPLC through a C18
column (Vydac) at a ﬂow rate of 1.5 mL/min. The mobile phases used
were as follows: solvent A (0.05% triﬂuoroacetic acid (TFA) in water)
and solvent B (0.05% TFA in acetonitrile). Peptides were eluted by a
gradient of 5%–100% solvent B over 60 min. The elution of peptides
was monitored by UV absorbance at 220 nm and by diversion of 20%
of the column ﬂow into the mass spectrometer. Mass spectra were
obtained on a Finnigan LCQ ion trap mass spectrometer (Finnigan)
with electrospray ionization (ESI). The ESI spectra (positive ionmode)
were collected from samples of 20 pmol/μL. The instrument was
calibrated by caffeine (m/z=195), the peptide MRFA (m/z=525),
and ultramark (m/z=1022, 1122, 1222, 1322, 1422, 1522, 1622).
2.2. In vitro mutagenesis of apoA-I cDNA
A pRc/RSV plasmid containing the cDNA of the wild-type human
apoA-I (kindly provided by Dr. Alessandro Sidoli) was used as a
template to create the two amyloidogenic variants Leu174Ser and
Leu75Pro. Mutations were carried out using an in vitro QuikChange
site-directed mutagenesis kit (Stratagene) and the appropriate
mutagenic primers. Leu174Ser ApoA-I vector was generated by
using 5'-CTG CGC CAG CGC TCG GCC GCG CGC CTT GAG-3' and 5'-
CTC AAG GCG CGC GGC CGA GCG CTG GCG CAG-3' as forward and
reverse primers, respectively. Similarly Leu75Pro apoA-I was created
by using 5'-TGG GAT AAC CCG GAA AAG GAG ACA GAG-3'and 5'-CTC
TGT CTC CTT TTC CGG GTT ATC CCA GAA CTC-3' as forward and
reverse primers. The underlined codons represent the site of
mutation. Mutagenesis was performed according to the manufac-
turer's protocol.
2.3. Transient transfection of COS-7 cells
COS-7 (monkey kidney) cells were plated on 6-well culture dishes
the day prior to transfection at a density of 1.5×106 cells/plate in
Dulbecco's modiﬁed Eagle's medium (DMEM; Gibco Brl) supplemen-
ted with streptomycin-penicillin, L-glutamine (4 mM), glucose
(4500 mg/L), sodium carbonate (1500 mg/L) and 10% foetal bovine
serum (FBS). Subconﬂuent COS-7 cells were rinsed once with serum-
free and antibiotic free medium (incomplete DMEM; Gibco Brl), and
transfected with wild-type or mutated apoA-I cDNAs using the
liposome transfection method (Lipofectamine 2000, Invitrogen). All
transfections were performed in triplicate. Transfection was carriedout for 6 hours by adding 5 μg/well DNA and 2.5 μL/well of
Lipofectamine 2000 to serum free transfection medium. Transfected
cells were washed twice with phosphate-buffered saline (PBS) to
remove the precipitate and than incubated with 2 mL DMEM
containing 10% FBS for an additional 12 h. Cell culture media were
then replaced with serum-free media supplemented with strepto-
mycin-penicillin and harvested after 48 h. Cells were then washed
with PBS and lysed with 25 mM Tris-phosphate, 2 mM dithiothreitol
(DTT), 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10%
glycerol, 1% Triton X-100). Intracellular extracts and supernatants
were stored at −20 °C until analysis.
2.4. Quantiﬁcation of apoA-I expression and secretion
The culture media and the cell lysates normalized for the cellular
protein content, together with increasing concentrations of puriﬁed
human apoA-I were loaded onto a 12% SDS-PAGE and proteins were
then transferred to polyvinylidene diﬂuoride membranes (HyBond-P,
GE Healthcare). Membranes were incubated with a polyclonal rabbit
anti-human apoA-I antibody (Dako, Denmark, 1:1000 dilution), and
subsequently with a polyclonal swine-anti-rabbit horseradish perox-
idase (Dako, Denmark, 1:10000 dilution). To exclude any signiﬁcant
difference in afﬁnity of the polyclonal antibodies for wild-type and
mutated species, we have tested these antibodies against recombi-
nant wild-type and variants, Leu75Pro and Leu174Ser, both expressed
and puriﬁed from CHO cell lines. Both the Western blot, performed
after SDS-PAGE of denatured apoA-I, and dot blot, directly performed
on native apoA-I, demonstrated that the mutation does not affect the
afﬁnity of the polyclonal antibodies.
Immunoblots were developed with an enhanced chemilumines-
cence system (ECL Plus, GE Healthcare) and apoA-I was visualized on
autoradiography ﬁlm (Hyperﬁlm, GE Healthcare). Images were
imported into Multi Gauge (FujiFilm) and apoA-I concentration in
the samples was calculated based on the standard apoA-I curve. Non-
parametric Kruskal–Wallis test was used to estimate the signiﬁcance
of the differences between intracellular and extracellular levels of
each variant versus wild-type.
Transfection efﬁciency was evaluated on cell lysates by real-time
PCR analysis. DNA was puriﬁed from aliquots of cell lysates per each
well, by phenol/chloroform extraction and wild-type, Leu174Ser or
Leu75Pro apoA-I genes were quantiﬁed on an Applied Biosystems
7900 sequence detector using SYBR® Green I and the following
speciﬁc primers: sense, ATCGAGTGAAGGACCTGGC and antisense,
AGCTTGCTGAAGGTGGAGGT. The primers amplify a 154-bp product.
Real-time detection was performed in a volume of 25 μL containing
100 nmol/L of each primer and iTaq SYBR Green Supermix with ROX
2X as recommended by the manufacturer (Bio-Rad). Conditions were
95 °C for 10 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 55 °C
and 30 s at 72 °C. A ﬁnal melting curve guaranteed the authenticity of
the target product. The housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used for normalization, with the
following speciﬁc primers: sense, CTTCACCACCATGGAGAAGGC and
antisense, AGTTGTCATGGATGACCTTGG [11]. All of the procedures
and calculation of the results were carried out according to
manufacturer's recommendations.
2.5. Immunoﬂuorescence microscopy
COS-7 cells, plated on 10-mm2 coverslips 24 h before transfection,
were transfected with the cDNAs of wild-type, Leu174Ser or Leu75Pro
apoA-I basically as reported in the transient transfection paragraph,
and analyzed 48 h later. In the experiments, the expression of wild-
type and apoA-I mutants was carried out simultaneously in order to
analyze the expression under identical transfection conditions. 15–
18 h before ﬁxation, cell culture media were replaced with serum free
media supplemented with streptomycin-penicillin. Cells were ﬁxed
Fig. 1. (a) Reversed-phase chromatography of V8 protease digestion of apoA-I puriﬁed
from HDL of a young carrier of the Leu75Pro mutation without clinical evidence of
amyloid deposits. The peptide indicated as 71–78 (sequence: FWDNLEKE) presents a
missed cleavage site. 71–78* (sequence: FWDNPEKE) is the peptide containing Pro75.
(b) ESI-Ion Trap Mass spectra of peptides 71–76 (eluted at 21.01 min), peptides 71–78
(eluted at 19.15 min) and peptides 71–78* carrying mutation (eluted at 15.15 min)
shown in panel a.
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with 0.1% saponin (Sigma). Primary and secondary antibodies were
incubated for 20 min with 0.1% saponin in PBS. The following
antibodies were used: a rabbit polyclonal anti-human apoA-I
(DAKO), a monoclonal anti-GM-130, identifying the Golgi structure
(BD Transduction Labs), a monoclonal anti-PDI, a marker of the
endoplasmic reticulum (Abcam) and a monoclonal anti-LAMP2, a
lysosomal protein (clone H4B4 kindly provided by the Developmental
Studies Hybridoma Bank University of Iowa, Iowa City, IA, USA) [12].
Secondary antibodies were immunoadsorbed FITC-conjugated don-
key anti-mouse IgG and TRITC-conjugated donkey anti-rabbit IgG and
purchased from Jackson ImmunoResearch Laboratories. Labelled
cover-slips were mounted using Mowiol reagent (Calbiochem) and
were inspected on an Olympus inverted ﬂuorescence microscope
(model IX70). Images were recorded with a digital CCD camera
(model C4742-95, Hamamatsu), using the IPLab spectrum V3.2
software package (Scanalytics, Inc.) and processed with Adobe
Photoshop 7.0 (Adobe Systems, Inc.).
3. Results
3.1. Clinical case
A 28-year-oldmale and a 44-year-oldwomanwere positive for the
Leu75Pro mutation at pre-symptomatic genetic test performed for
family history of apoA-I amyloidosis. They were subsequently
investigated to exclude early signs of the disease. Serum creatinine,
urinalysis, transaminases, alkaline phosphatase, N-Terminal pro-Brain
Natriuretic Peptide, gonadotropins and testosterone levels, in the
male patient, were all within the reference range. Total cholesterol,
HDL-cholesterol and apoA-I plasma concentrations were 103 mg/dL
(u.r.l. b 200), 35 mg/dL (normal levels≥45) and 105 mg/dL (reference
range 110–205) in the young man and 140 mg/dL, 43 mg/dL (normal
levels≥55) and 113 mg/dL (reference range 125–215) in the woman,
respectively. Abdominal ultrasound showed no abnormalities. An
abdominal fat aspirate was negative for amyloid deposits in both
subjects. After written informed consent, a 15-mL plasma sample was
obtained for puriﬁcation of total apoA-I from their circulating HDL.
3.2. Quantiﬁcation of the amyloidogenic apoA-I polypeptide in HDL
In the absence of an efﬁcient chromatographic method suitable for
the separation of the mutant from the wild-type apoA-I, the problem
of measuring both apoA-I species in heterozygous carriers of
amyloidogenic mutations was by-passed through the analysis of the
V8 protease digest derived from the full-length protein [7]. The
concentration of the mutated polypeptide in the young pre-
symptomatic carrier of the Leu75Pro mutation was even lower than
expected on the basis of the results obtained from previously
described patients [8] and represented less than 10% of the total
apoA-I chain. As shown in Fig. 1, the mutated chain in the young male
was detectable in mixture in the HPLC chromatograms. Similar results
were obtained using HDL from the second carrier analyzed (data not
shown).
3.3. Expression and secretion of the amyloidogenic variants in
mammalian cell models
The efﬁciency of secretion of wild-type apoA-I and Leu75Pro or
Leu174Ser variants was examined in transiently transfected COS-7
cells.
Transfection efﬁciency was measured in each experiment and no
signiﬁcant differences were found between wild-type apoA-I
and mutants (PN0.05). The average amount of Leu174Ser cDNA was
91.7±9.0% and that of Leu75Pro was 107.0±12.3% vs. cDNA of wild-
type apoA-I.ApoA-I levels in both cell lysates and culture media were
visualized by western blotting analysis (Fig. 2a). ApoA-I was
quantiﬁed in all samples using a calibration curve constructed with
known concentrations of apoA-I (Fig. 2a) and a linear plot in the
concentration range between 0.054 and 1 ng/μL was obtained (data
not shown). The results of three separate experiments are reported in
Fig. 2b where intra- and extra-cellular distribution of wild-type or
mutant apoA-I are compared. These results clearly indicate that the
relative amounts of the apoA-I secreted in the medium and the intra-
cytoplasmatic apoA-I are completely different when the cells
synthesize the wild-type rather than the amyloidogenic variants.
Both the Leu174Ser and Leu75Pro variants are largely retained within
the cells whereas wild-type apoA-I is mostly secreted in the medium.
Quantiﬁcation of total (intra- and extra-cellular) wild-type and
mutant apoA-I indicates that Leu174Ser and Leu75Pro are present at
lower amounts than the wild-type form. Particularly, the total
Leu174Ser was estimated 63±4.9 ng, the total Leu75Pro was 74±
13 ng, whereas wild-type apoA-I was 120±30 ng.
3.4. Sub-cellular localization of the amyloidogenic variants in
mammalian cell models
The intracellular distribution of wild-type and apoA-I mutants in
COS-7 cells was investigated by immunoﬂuorescence microscopy. Cells
transfected with wild-type apoA-I showed an intracellular distribution
of theprotein characterizedby a strong localization in theGolgi and faint
presence in the endoplasmic reticulum (ER); almost 87% of the cells
exhibit this intracellular distribution, as shown in Fig. 3a–d. On the
contrary, apoA-I mutants displayed an opposite localization, with a
Fig. 2. ApoA-I expression in COS-7 cell line. Wild-type apoA-I levels in COS-7 cytoplasm and medium were compared with Leu174Ser and Leu75Pro variants, respectively. Samples
from cell lysate and medium from transfected cells (at least three different wells) were analysed by Western blotting as described in Material and methods in three separate
experiments. Results of one experiment, for each variant, are reported in panel a. Average values (mean±SD) for the three experiments on each mutant are given in panel b, as
percentage of the total amount of expressed protein. Statistical signiﬁcance for pair wise comparison (variant versus wild-type) is represented by * for Pb0.05.
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shown in panel e-f for Leu75Pro, and in panel g-h for the Leu174Ser
mutant. Particularly, the phenotype related to the Leu174Ser mutant
wasmore extreme as 34% of the cells showed an exclusively ER pattern
suggesting a block of secretion. Interestingly, both apoA-I mutants
showed around 30% of the expressing cells with vacuolar and cytosolic
pattern (Fig. 4a) indicating cytosolic protein accumulation. This ﬁnding
suggests that the quality control degradative pathway has reached
saturation as a consequence of reduced secretion of both the mutated
apoA-I species. Those vacuolar structures were further characterized,
showing that they did not display co-localization neither with the ER
marker PDI, nor with the golgian GM130 protein (not shown), or with
the lysosomal protein Lamp2 (Fig. 4b–d) that suggests a similar nature
to the cytoplasmic droplets [13].
4. Discussion
A general assumption regarding the mechanisms of hereditary
amyloidosis is that, despite their propensity to misfold, the patho-
genic variants escape the quality control system, and are secreted as
much as the wild-type counterpart [14]. For certain amyloidogenic
proteins such as ﬁbrinogen [15] and several transthyretin variants
[16] this assumption is experimentally conﬁrmed by the presence, in
plasma, of an equimolar balanced concentration of both variant and
wild-type chains. These data would suggest that the intracellular
quality control, which is accustomed to remove not properly folded
proteins, cannot detect the intrinsic propensity to misfold and
aggregate caused by these mutations. However, in the case of peculiar
transthyretin species like the Asp18Gly and Ala25Thr variants, the
effect of these mutations on protein conformation is apparently
recognized by the quality control system and these peculiar variants
are signiﬁcantly retained in the ER of certain cellular models [5] and
forced to be degraded [17]. The natural clinical history of Asp18Gly
carriers is characterized by the presence of amyloid in the leptome-
ninges without any deposits in other tissues. Such a discrepancy was
apparently dictated by a low efﬁciency of the quality control of
choroid cells in recognizing and degrading this amyloidogenic variant
whereas a more effective quality control system of liver cells isFig. 3. ApoA-I expression in COS-7 cells. Exogenous apoA-I was expressed for 48 h. Panel a
localization with the Golgi matrix protein GM130 (cis-Golgi marker) in panel b. No evident co
isomerase (PDI), ER marker in panel d. Panels e–h show mutant apoA-I distribution in comp
respectively.capable of recognizing and blocking the secretion of the pathogenic
variant. The down-regulation of secretion of the amyloid protein
precursor and the consequent reduction of its concentration in the
body ﬂuids can therefore represent a ﬁrst line of defence of the
organism against the disease. Any clinical and biological evidence
suggesting the capacity of the cell to recognize the abnormal
conformation of amyloidogenic protein before the secretion should
be carefully studied because it could shed light on speciﬁc features of
the disease and can represent a highly sensitive therapeutic target.
Regarding the hereditary amyloidosis associated to mutations in the
apoA-I gene, we were the ﬁrst to discover a disequilibrium between
wild-type and the amyloidogenic variant in circulating HDL of
symptomatic patients carrying the mutation Leu174Ser or Leu75Pro
(7–8) and displaying histological evidence of amyloid deposits. That
observation was then conﬁrmed in other subjects with different
mutations, such as the Leu64Pro [9] and the Gly26Arg [18]. The
population expressing Leu75Pro apoA-I is the largest so far discovered
for this type of amyloidosis. More than 200 subjects heterozygous for
this mutation have been identiﬁed and they represent a highly
heterogeneous variety of clinical cases that are extremely informative
on the natural history of the disease. In particular, we have conﬁrmed
the disequilibrium between the wild-type and the mutated chain,
observed in symptomatic patients, also in two young carriers of the
mutation that were pre-symptomatic and free of any biochemical and
histological evidences of the disease. These data are clearly against the
hypothesis that the low plasma concentration of the Leu75Pro variant
can be simply ascribed to the absorption of the amyloidogenic chain
on the amyloid ﬁbrils and on the contrary strengthen the idea that a
reduced cellular secretion might substantially contribute to the chain
imbalance in HDL. The latter hypothesis has been explored by
studying the expression and the secretion of two amyloidogenic
variants, Leu174Ser and Leu75Pro, in a mammalian cell line, COS-7
cells. These non-hepatic, non-lipoprotein-producing cells do not
express endogenous apoA-I, constitutively. COS-7 cells have been
previously used for monitoring the intracellular trafﬁcking and the
expression of variants of human apoA-I [19] since they can produce
and secrete apoA-I upon transient transfection even if with a lower
efﬁciency compared with hepatic cells. Our results show that the totalshows wild-type apoA-I distribution in the Golgi compartment as displayed by the co-
-localization is present between wild-type apoA-I in panel c, and the protein disulphide
arison with cis-Golgi staining, for Leu75Pro in panels e–f, and Leu174Ser in panels g-h,
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Fig. 4. ApoA-I expression and vacuolar structures. Panel a shows vacuolar and cytosolic staining for apoA-I Leu174Ser mutant. No evident co-localization is detected between apoA-I
positive vacuoles and the lysosomal protein Lamp-2, as shown in panels c, d and in the overlay, panel b, in wild-type cells.
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wild-type apoA-I. No differences in transfection efﬁciency were
detected among apoA-I types, therefore an intracellular degradation
of the two amyloidogenic variants could explain the observed results.
A remarkable difference in the ratio between intracellular and
secreted apoA-I was found in COS-7 cells expressing the wild-type or
the amyloidogenic variants. The amyloidogenic Leu174Ser and
Leu75Pro apoA-I resulted entrapped in the ER, whereas the wild-
type was mainly localized in the Golgi. Furthermore, both the
cytoplasm outside the ER and the Golgi contained apoA-I aggregates
adopting a doughnut like shape that remind the apoA-I aggregates
localized in the cells expressing other variants of apoA-I associated
with hypoalphalipoproteinemia rather than amyloidosis [20]. The
cells appeared unable to dispose of the misfolded and aggregated
apoA-I that was sequestered in the ER and well separated from the
lysosomal system, which, on the contrary, is known to efﬁciently
interact with amyloidogenic proteins and contribute to their
catabolism as reported in other models of intracellular accumulation
of amyloidogenic proteins [21]. Altogether our results suggest that
circulating levels of apoA-I variants are signiﬁcantly affected by an
impairment in their secretion. It should be noted that an impaired
secretion would not be a unique feature of amyloidogenic apoA-I
variants, since it has been also demonstrated in primary hepatocytes
for non-amyloidogenic apoA-I mutations [22,23]. In addition to an
impaired secretion, data reported by Rader et al. [24], regarding the in
vivo metabolism of the Arg26Gly apoA-I, clearly demonstrated a
reduced half-life of the variant in comparison to the wild-type, thus
suggesting that the low plasma level of the variant might be also due
to a faster uptake of the protein in a metabolically active target tissue.
Overall, how even very low plasma concentrations of the variants may
cause the disease at target tissues remains an intriguing and open
issue. It is possible that the persistently low concentration of the
precursor may be at the basis of both the slow progression of thedisease and the relatively benign phenotype of this condition, thus
representing a protective mechanism.
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